NCT03536143View on ClinicalTrials.gov

A Phase I/II Study of KB103, a Topical HSV1-COL7, on DEB Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 6, 2018

Primary Completion Date

November 1, 2019

Study Completion Date

November 1, 2019

Conditions
Dystrophic Epidermolysis Bullosa
Interventions
BIOLOGICAL

Topical beremagene geperpavec

Topical gel of non-integrating, replication-incompetent HSV-1 expressing the human collagen VII protein

BIOLOGICAL

Placebo gel

Placebo gel

Trial Locations (1)

94305

Stanford University, Stanford

Sponsors
All Listed Sponsors
lead

Krystal Biotech, Inc.

INDUSTRY

NCT03536143 - A Phase I/II Study of KB103, a Topical HSV1-COL7, on DEB Patients | Biotech Hunter | Biotech Hunter